#ScienceSaturday ❓ Some people with multiple myeloma respond well to CAR T-cell therapy, but others relapse when the cancer finds ways to hide. Why does that happen, and how can we fix it? ➡️ Dr. Fabiana Perna and colleagues at Moffitt Cancer Center, found that one reason is that some myeloma cells don’t have enough of a target protein called BCMA, which CAR T cells need to find and attack the cancer. ➡️ To solve this, the team designed a new kind of CAR T cell that looks for a different target called SEMA4A. This protein is common on myeloma cells—even in patients whose cancer came back after BCMA-CAR T therapy. ➡️ In lab and mouse studies, these SEMA4A-CAR T cells destroyed myeloma cells that regular BCMA-CAR T cells couldn’t reach, showing promise for treating relapsed patients in the future. 🌟 This research could lead to next-generation cell therapies that keep multiple myeloma from coming back and help more patients stay cancer-free longer. @fabianaperna @MoffittNews 🔗 Read more in Cancer Cell: doi.org/10.1016/j.ccell.2025…